Trial Profile
A phase III trial of Heartcel in patients with cardiomyopathy
Status:
Suspended
Phase of Trial:
Phase III
Latest Information Update: 08 Jul 2020
Price :
$35
*
At a glance
- Drugs CLXR 001 (Primary)
- Indications Cardiomyopathies
- Focus Therapeutic Use
- 06 Jul 2020 Status changed from recruiting to suspended, according to a Celixir meida release.
- 06 Jul 2020 According to a Celixir meida release, recruitment in this study is scheduled to recommence under a new CTA in Q3 2020 and the study is expected to complete in 2021.
- 06 Jul 2020 According to a Celixir meida release, after consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), the company has decided to suspend this study due to covid-19 pandemic. The company has decided to replace the current clinical trial application (CTA) with a revised protocol.